Following the release of encouraging clinical trial data, shares of NanoViricides, Inc. (NYSE: NNVC) are demonstrating a bullish trend on US stock charts. As of the latest current-market check, NNVC stock increased by 7.92% to $3.27.
- Breakthrough Findings On NV-387
- Efficacy Across Multiple Models
- Potential Revolutionary Antiviral Agent
Breakthrough Findings On NV-387
NanoViricides (NNVC) reported that its leading clinical-stage broad-spectrum antiviral drug candidate, NV-387, exhibits an ideal flat blood concentration profile for an extended duration upon oral administration in two different animal models. This rare but highly desirable extended flat time profile of NV-387 in the bloodstream enables a sustained antiviral effect over a prolonged period, allowing for infrequent dosing regimens.
Specifically, the blood concentration of NV-387 peaked within the first hour and remained nearly constant for eight hours or longer. Subsequently, the concentration declined to baseline at around twelve hours following the oral administration of the initial dose. This was consistently observed in studies involving rats and dogs.
Efficacy Across Multiple Models
Additionally, NanoViricides recently reported that when NV-387 was administered as a slow bolus intravenous infusion, it resulted in a relatively flat blood concentration plateau with a very slow decline over a 24-hour period in a cynomolgus monkey model. The company had previously demonstrated that orally administered NV-387 produced strong antiviral effects against several respiratory viruses.
In lethal infections with hCoV-NL63, RSV, and Influenza A/H3N2, orally administered NV-387 outperformed approved therapeutics where available. Notably, in a rat model of deadly lung infection with RSV A2, NV-387 allowed for the full recovery from RSV infection.
Potential Revolutionary Antiviral Agent
First-in-class, broad-spectrum antiviral medication NV-387, may revolutionize treatment for viruses including RSV, COVID-19, influenza, and maybe others. NNVC's claim is also supported by non-clinical pharmacokinetic studies of the medication when administered orally that NV-387's systemic circulation and direct antiviral actions are responsible for the strong antiviral effects shown in animal efficacy trials.
NanoViricides also highlighted that NV-387 may be among the first or one of the few nanomedicines effective upon oral administration, a notable advancement given that nanomedicines are typically restricted to injectable or topical delivery methods.
纳米病毒杀手公司(NanoViricides, Inc.)股票(NYSE: NNVC)发布了令人鼓舞的临床试验数据后,在美国股票图表上显示出看好的趋势。截至最新的当前市场检查,NNVC股票上涨7.92%至3.27美元。
- 关于NV-387的突破性发现
- 多个模型下的疗效
- 潜在的革命性抗病毒药物
关于NV-387的突破性发现
纳米病毒杀手(NNVC)报告称,其主要临床阶段的广谱抗病毒药物候选者NV-387,在两种不同的动物模型中口服后呈现出理想的平稳血浓度曲线。NV-387在血液中的这种罕见但极为理想的延长平稳时间曲线,可在较长时间内实现持续的抗病毒效果,从而允许不频繁的给药方案。
具体地,NV-387在首小时内浓度最高,口服后血液浓度一直保持稳定,持续八小时以上。随后,在大鼠和狗的研究中一致地观察到初始剂量口服后十二小时左右,浓度降至基线。
多个模型下的疗效
此外,纳米病毒杀手最近报告称,在长尾猴模型中,缓慢推注NV-387导致相对平稳的血浓度平台,血浓度在24小时内缓慢下降。该公司此前已证明,口服NV-387对几种呼吸道病毒具有强烈的抗病毒作用。
在Lethal Infections with HCoV-NL63、RSV和Influenza A/H3N2中,口服NV-387表现超过现有已批准的治疗药物。值得注意的是,在针对RSV A2的致命肺部感染的大鼠模型中,NV-387可以让病情完全恢复。
潜在的革命性抗病毒药物
首个广谱抗病毒药NV-387可能通过革新治疗方法革新多种病毒的治疗方法,包括RSV、COVID-19、流感等。NNVC的主张也得到了该药物口服时的非临床药代动力学研究的支持。NV-387的系统循环和直接抗病毒作用是动物疗效试验中强烈的抗病毒效果的原因。
此外,纳米病毒杀手还强调,NV-387可能是口服后有效的头一批或少数纳米医学,这是一个值得注意的进步,因为纳米医学通常限制在注射或局部给药方法。